Last reviewed · How we verify
Nifekalant hydrochloride
At a glance
| Generic name | Nifekalant hydrochloride |
|---|---|
| Also known as | Nifekalant Hydrochloride for Injection |
| Sponsor | Sichuan Baili Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery (PHASE3)
- Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation (PHASE4)
- Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection
- Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nifekalant hydrochloride CI brief — competitive landscape report
- Nifekalant hydrochloride updates RSS · CI watch RSS
- Sichuan Baili Pharmaceutical Co., Ltd. portfolio CI